AstraZeneca (AZN) Expected to Announce Earnings on Thursday

AstraZeneca (NASDAQ:AZN) is anticipated to post its quarterly earnings results before the market opens on Thursday, February 6th. Analysts expect AstraZeneca to post earnings of $1.10 per share and revenue of $14.19 billion for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.

AstraZeneca (NASDAQ:AZN) last announced its earnings results on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, beating analysts’ consensus estimates of $1.01 by $0.03. The business had revenue of $13.57 billion during the quarter, compared to analysts’ expectations of $13.08 billion. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The business’s revenue was up 18.0% compared to the same quarter last year. During the same period in the prior year, the company earned $0.87 earnings per share. On average, analysts expect AstraZeneca to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

AstraZeneca Stock Performance

Shares of AZN stock opened at $68.96 on Wednesday. AstraZeneca has a 52-week low of $60.47 and a 52-week high of $87.68. The stock’s 50-day moving average price is $67.15 and its 200 day moving average price is $73.79. The company has a quick ratio of 0.71, a current ratio of 0.93 and a debt-to-equity ratio of 0.71. The stock has a market capitalization of $213.85 billion, a PE ratio of 33.00, a price-to-earnings-growth ratio of 1.18 and a beta of 0.46.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on AZN shares. UBS Group upgraded AstraZeneca from a “sell” rating to a “neutral” rating in a research report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. Two investment analysts have rated the stock with a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Buy” and an average target price of $89.75.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.